This is the authors' abstract. We don't add key points for this paper.
A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: